Double-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference11 articles.
1. Third generation calcium entry blockers;Toyo-oka;Blood Press,1996
2. Sympathetic hyperactivity and coronary risk in hypertension;Julius;Hypertension,1993
3. Third generation calcium antagonists: Further developments;van;Blood Press,1996
4. Lercanidipine: Short plasma half-life, long duration of action;Herbette;J Cardiovasc Pharmacol,1997
5. Activity of lercanidipine administered in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension;Ambrosioni;J Cardiovasc Pharmacol,1997
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dihydropyridine calcium antagonists: conscious choice;Systemic Hypertension;2017-03-15
2. Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study;High Blood Pressure & Cardiovascular Prevention;2017-01-06
3. Lercanidipine in the management of hypertension: An update;Journal of Pharmacology and Pharmacotherapeutics;2017
4. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice;Expert Opinion on Pharmacotherapy;2007-10
5. Lercanidipine in the Treatment of Hypertension;Annals of Pharmacotherapy;2007-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3